AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Biote Reports Q2 EPS 10c, Revenue $48.9M, Beats Estimate
ByAinvest
Thursday, Aug 7, 2025 4:09 am ET1min read
Biote reported Q2 EPS of 10 cents, beating the consensus estimate of 13 cents. Revenue was $48.9M, slightly below the consensus of $49.5M. The company initiated an organizational restructuring to drive profitable growth and reported a 19.1% YoY increase in Adjusted EBITDA. Biote is focused on advancing its strategic priorities, including accelerating new providers, maximizing value from top-tier clinics, and strengthening its commercial organization.
Biote Corp. (BTMD) reported its second-quarter (Q2) 2025 earnings, with earnings per share (EPS) of 10 cents, surpassing the consensus estimate of 13 cents. Revenue for the quarter was $48.9 million, slightly below the consensus estimate of $49.5 million. The company also announced a significant organizational restructuring aimed at driving profitable growth [1].The company's adjusted EBITDA increased by 19.1% year-over-year (YoY), reflecting a shift in the annual marketing event and efficiency gains from the vertical integration of its 503B manufacturing facility. Biote's gross profit margin improved to 71.6% from 68.8%, and net income turned positive at $3.9 million, compared to a net loss of $10.4 million in the prior year [2].
Biote's CEO, Bret Christensen, highlighted the progress made in reorganizing the commercial organization and aligning with strategic priorities, such as accelerating new providers, maximizing value from top-tier clinics, and strengthening the commercial organization. The company revised its fiscal 2025 revenue guidance to be greater than $190 million, up from the previously disclosed range of $202-$208 million, and Adjusted EBITDA guidance to be greater than $50 million, up from the previously disclosed range of $59-$64 million [2].
The stock has lost about 32.5% since the beginning of the year, compared to the S&P 500's gain of 7.1%. The company's earnings surprise of +66.67% this quarter and a history of beating consensus EPS estimates four times over the last four quarters suggest a positive trajectory for the stock [1].
References:
[1] https://www.nasdaq.com/articles/biote-corp-btmd-tops-q2-earnings-estimates
[2] https://finance.yahoo.com/news/biote-reports-second-quarter-2025-200500062.html
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments

No comments yet